WuXi AppTec Soars as Chinese Pharma Raises 2025 Profit Outlook

Select Language:

Shares of WuXi AppTech experienced a boost after the pharmaceutical giant in China raised its annual revenue forecast for the third time this year, driven by gains from the sale of equity in affiliated companies and the divestment of certain business units.

The company closed 6 percent higher today in Shanghai at CNY104.60 (approximately USD15), while its stock listed in Hong Kong closed up 8.3 percent at HKD120 (about USD15.39).

The firm projects its net profit for last year more than doubled, reaching CNY19.2 billion (around USD2.8 billion), up from 2024. Revenue is expected to have increased by 15 percent to CNY45.5 billion, with revenue from ongoing operations up 21 percent.

Earlier in March, the company forecasted its annual revenue would grow between 10 percent and 15 percent, reaching between CNY41.5 billion and CNY43 billion. This outlook was raised to as much as CNY43.5 billion in July and then to CNY44 billion in October.

Excluding non-recurring gains and losses, profit climbed 33 percent last year to CNY13.2 billion compared to the previous year.

The company maintained its focus on contract research, development, and manufacturing this year, expanding production capacity, optimizing manufacturing processes, and enhancing operational efficiency to support sustainable growth.

In the past year, WuXi AppTech sold part of its stake in WuXi XDC Cayman, a bioconjugation drug research and development service provider, earning CNY4.2 billion (approximately USD602.1 million) in net profit. Additionally, it sold 100 percent of its clinical research service subsidiaries, WuXi Clinical and WuXi MedKey, generating CNY1.4 billion.

The company’s net profit in the third quarter surged 53 percent year-over-year to CNY3.5 billion, while revenue increased 15 percent to CNY12.1 billion, according to a quarterly report released in October.

For the first nine months of last year, net profit jumped 85 percent to CNY12.1 billion, while revenue grew 19 percent to CNY32.9 billion. Income from U.S. clients rose 32 percent, reaching CNY22.2 billion.